Advertisement

Receptors for (3–8) Angiotensin in Brain Cells

AngIV Binding in Brain Cells
  • Conrad Sernia
  • Bruce Wyse
  • Siok-Keen Tey
  • Su-Lin Leong
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 396)

Abstract

Angiotensin II (AngII) is the peptide effector hormone of the blood renin-angiotensin system (RAS). Central to the role of the RAS as a hormonal regulator of cardiovascular function are the actions of AngII on vascular tone and on fluid and electrolyte homeostasis (1). It is commonly accepted that the functions of the blood RAS are supported by local angiotensin-generating systems in various tissues, including the heart, kidney, adrenal, blood vessels and brain (2–4). Hence, production of Angll in particular brain areas can lead to hypertensive changes in the periphery.(3,5,6).

Keywords

High Pressure Liquid Chromatography Radioreceptor Assay Phase High Pressure Liquid Chromatography Primary Glial Cell AngII Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eberhardt, R.T., Kevak, R.M., Kang, P.M. and Frishman, W.H. (1993). J. Clin. Pharmacol. 33: 1023–1028.PubMedCrossRefGoogle Scholar
  2. 2.
    Campbell, D. J. (1987). J. Cardiovasc. Pharmacol. 10: S1–S8PubMedCrossRefGoogle Scholar
  3. 3.
    Phillips, M.I., Speakman, E.A. and Kimura, B. (1993). Regul. Peptides 43: 1–20.CrossRefGoogle Scholar
  4. 4.
    Brown, L. and Sernia, C. (1994). Exp. Physiol. Pharmacol. 21: 811–818.CrossRefGoogle Scholar
  5. 5.
    Bunnemann, B., Fuxe, K. and Ganten, D. (1993). Regul. Peptides 46: 487–509.CrossRefGoogle Scholar
  6. 6.
    Saavedra, J.M. (1992). Endocr. Revs. 13: 329–386Google Scholar
  7. 7.
    Ferrario, C. M., Brosnihan, K. B., Diz, D. I., Jaiswal, N., Khosla, M. C., Milsted, A. and Tallant, E. A. (1991). Hypertension 18: (Suppl. III): S126–S133.Google Scholar
  8. 8.
    Coleman, J.K.M., Krebbs, L., Ong, B., Hanesworth, J.M., Lawrence, K.A., Harding, J.W. and Wright, J.W.(1992). FASEB. J. 6: A437.Google Scholar
  9. 9.
    Harding, J.W., Cook, V.I. Miller-Wing, A.V., Hanesworth, J.M., Sardinia, M.F, Hall, K.L., Stobb, J.W., Swanson, G.N, Coleman, J.K.M., Wright, J.W. and Harding, E.C. (1992). Brain. Res. 583: 340–343PubMedCrossRefGoogle Scholar
  10. 10.
    Swanson, G.N., Hanesworth, J.M., Sardinia, M.F., Coleman, J.K.M., Wright, J.W, Hall, K.L., Miller-Wing, A.V., Stobb, J.W, Cook, V.I., Harding, E.C. and Harding, J.W.(1992) Regul. Peptides 40: 409–419.CrossRefGoogle Scholar
  11. 11.
    Wright, J.W., Miller-Wing, A.V., Shaffer, M.J., Higginson, C., Wright, D.E., Hanesworth, J.M. and Harding, J.W.(1993).Brain Res. Bull. 32: 497–502PubMedCrossRefGoogle Scholar
  12. 12.
    Sardinia, M.F., Hanesworth, J.M., Krebs, L.T. and Harding J.W. (1993). Peptides 14: 949–954.PubMedCrossRefGoogle Scholar
  13. 13.
    Hall, K.L., Hanesworth, J.M., Ball, A.E., Felgenhaur, G.P., Hosick, H.L. and Harding, J.W.(1993). Regul. Peptides 44: 225–232.CrossRefGoogle Scholar
  14. 14.
    Hanesworth, J.M., Sardinia, MF., Krebs, L. T., Hall, K.L. & Harding, J.W.(1993). J. Pharmacol. Exper. Ther. 266: 1036–1042.Google Scholar
  15. 15.
    Wright, J.W. and Harding, J.W.(1994). Neurosci. Biobehav. Rev. 18: 21–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Whitebread, S., Mele, M., Kamber, B. and deGasparo, M.(1989). Biochem. Biophys. Res. Commun. 163: 284–291.PubMedCrossRefGoogle Scholar
  17. 17.
    Timmermans, P.B., Wong, P.C., Chiu, A.T. and Harblin, W.F.(1991). Trends Pharmacol. Sci. 12: 55–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Stecklings, U.M., Bottari, S.P. and Unger, T. (1992).TIPS. 13: 365–368.Google Scholar
  19. 19.
    Bernier, S.G., Fournier, A. and Guillemette, G.(1994). Eur. J. Pharmacol. 271: 55–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Jarvis, M.F., Gessner, G.W. and Ly, C.Q. (1992). Eur. J. Pharmacol. 219: 319–322.PubMedCrossRefGoogle Scholar
  21. 21.
    Haberl, R.L., Decker, P.J. and Einhaupl, K.M.(1991). Circ. Res. 68: 1621–1627.PubMedCrossRefGoogle Scholar
  22. 22.
    Braszko, J.J., Kupryszewski, G., Witczuk, B. and Wisniewski, K.(1988) Neurosci. 27: 777–783.CrossRefGoogle Scholar
  23. 23.
    Baker, K.M. and Aceto, J.F. (1990). Am. J. Physiol. 259: H610–H618.PubMedGoogle Scholar
  24. 24.
    Miller-Wing, A. V., Hanesworth, J. M., Sardinia, M. F., Hall, K. L., Wright, J. W., Speth, R. C., Grove, K. L. and Harding, J. W. (1993). J. Pharmacol. Exp. Ther. 266: 1718–1726.PubMedGoogle Scholar
  25. 25.
    Hagiwara, N., Imada, S. & Sueoka, N. (1993). J. Neurosci Res 36, 646–656.PubMedCrossRefGoogle Scholar
  26. 26.
    Thomas, W.G., Greenland, K.J., Shinkel, T.A. and Sernia, C. (1992). Brain Res. 588: 191–200.PubMedCrossRefGoogle Scholar
  27. 27.
    Beck, J.S. and Goren, H.J.(1983). J. Receptor Res. 3: 561–577.Google Scholar
  28. 28.
    Sernia C.(1995). Regul. Peptides 57: 1–18.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Conrad Sernia
    • 1
  • Bruce Wyse
    • 1
  • Siok-Keen Tey
    • 1
  • Su-Lin Leong
    • 1
  1. 1.Neuroendocrine Laboratory, Department of Physiology and PharmacologyUniversity of QueenslandQueenslandAustralia

Personalised recommendations